IDYA IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.

$19.83  +1.00 (5.28%)
As of 03/05/2021 15:59:51 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA
USA
05/23/2019
29,069,719
127,793
$575,871,133
0.00%
SEC Edgar Online
10-Q
10-K
45166A102
US45166A1025
BK0VHF6

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-116.90
2.94
64.22
-20.54%
-447.65%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy